Discover
IMMX
Immix Biopharma, Inc.
9.83
2 x 7.30
2 x 12.33
bid
ask
-
0.48
4.66%
2 @ 07:19 AM
9.83 +0.00 (0.00%)
| Ytd | 87.95% | |
| 1y | 348.86% |
9.60
day range
10.29
1.94
52 week range
11.61
| Open | 10.15 | Prev Close | 10.31 | Low | 9.60 | High | 10.29 | Mkt Cap | 699.80M |
| Vol | 1.82M | Avg Vol | 1.36M | EPS | -0.92 | P/E | N/A | Forward P/E | -3.96 |
| Beta | 0.10 | Short Ratio | 2.94 | Inst. Own | 17.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 9.24 | 200-d Avg | 6.61 | 1yr Est | 7.00 |
| Income Statement | |||
| Operating Expenses | 10.80M | ||
| Research and Development Expense | 5.98M | ||
| Selling, General and Administrative Expense | 4.82M | ||
| Operating Income | -10.80M | ||
| Net Income | -10.09M | ||
| Net Income Common Stock | -10.09M | ||
| Net Income Common Stock (USD) | -10.09M | ||
| Consolidated Income | -10.09M | ||
| Earnings per Basic Share | -0.18 | ||
| Earnings per Basic Share (USD) | -0.18 | ||
| Earnings per Diluted Share | -0.18 | ||
| Earning Before Interest & Taxes (EBIT) | -10.09M | ||
| Earning Before Interest & Taxes (USD) | -10.09M | ||
| Weighted Average Shares | 55.37M | ||
| Weighted Average Shares Diluted | 55.37M | ||
| Balance Sheet | |||
| Cash and Equivalents | 79.25M | ||
| Cash and Equivalents (USD) | 79.25M | ||
| Investments | 11.33M | ||
| Investments Current | 11.33M | ||
| Current Assets | 92.27M | ||
| Property, Plant & Equipment Net | 3.36M | ||
| Total Assets | 95.82M | ||
| Debt Current | 125.39K | ||
| Total Debt | 1.04M | ||
| Current Liabilities | 10.54M | ||
| Debt Non-Current | 912.34K | ||
| Total Liabilities | 11.45M | ||
| Accumulated Retained Earnings (Deficit) | -114.55M | ||
| Accumulated Other Comprehensive Income | 105.64K | ||
| Shareholders Equity | 84.36M | ||
| Shareholders Equity (USD) | 84.36M | ||
| Assets Non-Current | 3.54M | ||
| Total Debt (USD) | 1.04M | ||
| Liabilities Non-Current | 912.34K | ||
| Trade and Non-Trade Payables | 10.41M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 130.77K | ||
| Net Cash Flow from Financing | -37.56K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -14.68M | ||
| Capital Expenditure | -32.49K | ||
| Issuance (Purchase) of Equity Shares | 33.53K | ||
| Net Cash Flow from Investing | -4.80M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -4.77M | ||
| Net Cash Flow from Operations | -9.83M | ||
| Effect of Exchange Rate Changes on Cash | -12.81K | ||
| Share Based Compensation | 575.57K | ||